The US Food and Drug Administration (FDA) has allowed Aidoc to use artificial intelligence (AI) algorithms for the detection and prioritisation of incidental findings associated with Covid-19.
The AI algorithms detect findings associated with Covid-19 in CT studies that contain the lung or part of the lung such as chest, abdomen or cervical spine.
Prioritisations of the incidental findings may help manage the adverse effects of Covid-19 by providing adjunctive information that can promote further patient evaluation, the company noted.
According to studies published by universities of Brussels, Chicago and Brescia and a report from Maimonides Medical Center in New York, radiologists have discovered that 8%-10% of patients undergoing CT scans for other conditions are affected by Covid-19.
These patients, who did not exhibit any respiratory symptoms related to the disease, were undergoing oncology screenings or being screened for abdominal pain.
The prompt identification of the incidental findings enables immediate treatment or appropriate isolation.
In a statement, Aidoc said: “Ahead of an expected surge of delayed elective medical imaging due to the Covid-19 pandemic, Aidoc’s solutions form a vital safety net that will help healthcare systems responsibly and efficiently address urgent, life-threatening conditions while managing their backlogs.”
The product is the latest addition to the company’s suite of AI radiology solutions that have secured the FDA and CE clearances.
The product can detect critical conditions such as intracranial haemorrhage, large-vessel occlusion, PE in pulmonary angiography and cervical spine fractures among others.
Aidoc specialises in AI solutions that support and enhance radiologist diagnostic capabilities. The company has four FDA-cleared and six CE-marked solutions that are in clinical use at approximately 300 medical centres globally.